Skip to main content
Premium Trial:

Request an Annual Quote

AxCell Wins US Patent Covering Synthetic Ligand-Based Proteomic Technology

NEW YORK, Nov. 1 - AxCell Biosciences has been awarded a US patent covering nine claims to the company's Cloning of Ligand Targets proteomics technology, AxCell said on Thursday.

“This technology permits the use of ligands … to discover new domains and ultimately new proteins that may be useful as drug targets,” John Rodwell, president and chief technical officer of AxCell, said in a statement.

The patent, numbered 6,309,820 and entitled “Polypeptides Having a Functional Domain of Interest and Methods of Identifying and Using Same,” deals with a technology that AxCell says can enable researchers to measure protein interactions “in an industrialized, high-throughput manner.”

The nine claims deal cover the methods by which AxCell “identified SH3 domain-containing proteins from human protein expression libraries,” the company said in the statement. According to Princeton, NJ-based AxCell, proteins with these domains “play a role” in cancer, cardiovascular disease, central nervous system disorders, diabetes, and inflammatory disease.

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.